Eli Lilly and Company (LLY) Stock Forecast, Price Target & Predictions
LLY Stock Forecast
Eli Lilly and Company stock forecast is as follows: an average price target of $753.65 (represents a -18.41% downside from LLY’s last price of $923.71) and a rating consensus of 'Buy', based on 19 wall street analysts offering a 1-year stock forecast.
LLY Price Target
The average price target for Eli Lilly and Company (LLY) is $753.65 based on 1-year price targets from 19 Wall Street analysts in the past 3 months, with a price target range of $1.15K to $300.00. This represents a potential -18.41% downside from LLY's last price of $923.71.
LLY Analyst Ratings
According to 19 Wall Street analysts, Eli Lilly and Company's rating consensus is 'Buy'. The analyst rating breakdown for LLY stock is 0 'Strong Buy' (0.00%), 18 'Buy' (94.74%), 1 'Hold' (5.26%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Eli Lilly and Company Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Peter Verdult | Citigroup | $1.06K | $935.02 | 13.37% | 14.75% |
| Aug 27, 2024 | Terence Flynn | Morgan Stanley | $1.11K | $957.51 | 15.51% | 19.73% |
| Aug 14, 2024 | Kerry Holford | Berenberg Bank | $1.05K | $908.05 | 15.63% | 13.67% |
| Aug 12, 2024 | James Shin | Deutsche Bank | $1.02K | $891.68 | 14.95% | 10.97% |
| Aug 09, 2024 | Chris Shibutani | Goldman Sachs | $856.00 | $891.68 | -4.00% | -7.33% |
| Aug 09, 2024 | Mohit Bansal | Wells Fargo | $1.00K | $845.31 | 18.30% | 8.26% |
| Aug 09, 2024 | Evan David Seigerman | BMO Capital | $1.10K | $845.31 | 30.25% | 19.19% |
| Aug 09, 2024 | Geoff Meacham | Bank of America Securities | $1.15K | $845.31 | 36.04% | 24.50% |
| Jul 11, 2024 | Terence Flynn | Morgan Stanley | $1.08K | $939.78 | 15.24% | 17.24% |
| Jul 11, 2024 | Kerry Holford | Berenberg Bank | $1.00K | $939.78 | 6.41% | 8.26% |
The latest Eli Lilly and Company stock forecast, released on Sep 13, 2024 by Peter Verdult from Citigroup, set a price target of $1.06K, which represents a 13.37% increase from the stock price at the time of the forecast ($935.02), and a 14.75% increase from LLY last price ($923.71).
Eli Lilly and Company Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 12 | 25 |
| Avg Price Target | $1.08K | $1.04K | $933.92 |
| Last Closing Price | $923.71 | $923.71 | $923.71 |
| Upside/Downside | 17.24% | 12.49% | 1.11% |
In the current month, the average price target of Eli Lilly and Company stock is $1.08K, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 17.24% increase as opposed to Eli Lilly and Company's last price of $923.71. This month's average price target is up 4.23% compared to last quarter, and up 15.96% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 13, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 09, 2024 | Jefferies | Underperform | Underperform | Hold |
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 27, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Aug 27, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 16, 2024 | Guggenheim | Buy | Buy | Hold |
| Aug 12, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 12, 2024 | Deutsche Bank | Hold | Buy | Upgrade |
| Aug 09, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
Eli Lilly and Company's last stock rating was published by BMO Capital on Sep 13, 2024. The company gave LLY a "Outperform" rating, the same as its previous rate.
Eli Lilly and Company Financial Forecast
Eli Lilly and Company Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $6.96B | $7.30B | $6.94B | - | $7.81B | $8.00B | $6.77B | $6.74B | $6.81B | $7.44B | $5.74B | $5.50B | $5.86B | $6.11B | $5.48B | $5.64B | $5.09B | $6.44B | $6.06B |
| Avg Forecast | $15.32B | $14.21B | $13.54B | $13.50B | $13.95B | $12.22B | $9.98B | $8.94B | $8.95B | $8.97B | $7.58B | $6.86B | $7.33B | $6.89B | $6.85B | $7.29B | $7.69B | $6.64B | $6.60B | $6.93B | $7.27B | $5.88B | $5.76B | $5.49B | $5.91B | $5.50B | $5.58B | $5.20B | $5.68B | $5.15B |
| High Forecast | $15.88B | $14.74B | $14.03B | $13.99B | $14.46B | $12.60B | $10.35B | $9.26B | $9.20B | $9.53B | $7.86B | $7.12B | $7.60B | $7.14B | $6.85B | $7.62B | $8.04B | $6.94B | $6.90B | $7.25B | $7.60B | $6.15B | $6.03B | $5.74B | $6.19B | $5.75B | $5.84B | $5.44B | $6.82B | $6.19B |
| Low Forecast | $14.56B | $13.51B | $12.86B | $12.83B | $13.25B | $11.87B | $9.48B | $8.49B | $8.73B | $8.29B | $7.20B | $6.52B | $6.97B | $6.54B | $6.85B | $7.05B | $7.44B | $6.42B | $6.38B | $6.71B | $7.03B | $5.68B | $5.58B | $5.31B | $5.72B | $5.32B | $5.40B | $5.03B | $4.54B | $4.12B |
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.01% | - | 1.07% | 1.04% | 1.02% | 1.02% | 0.98% | 1.02% | 0.98% | 0.95% | 1.07% | 1.03% | 1.00% | 1.01% | 0.98% | 1.13% | 1.18% |
Eli Lilly and Company's average Quarter revenue forecast for Jun 23 based on 6 analysts is $7.58B, with a low forecast of $7.20B, and a high forecast of $7.86B. LLY's average Quarter revenue forecast represents a 8.95% increase compared to the company's last Quarter revenue of $6.96B (Mar 23).
Eli Lilly and Company EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-6.07B | $-6.09B | $1.70B | $2.39B | $2.40B | - | $2.74B | $2.37B | $1.71B | $2.05B | $1.91B | $2.93B | $1.89B | $2.06B | $2.05B | $2.10B | $1.80B | $1.82B | $4.85B | $1.36B | $1.90B |
| Avg Forecast | $4.94B | $4.58B | $4.36B | $4.35B | $4.50B | $3.94B | $3.22B | $2.08B | $2.88B | $2.89B | $2.44B | $1.89B | $2.36B | $1.92B | $2.21B | $1.72B | $2.34B | $1.75B | $2.07B | $2.15B | $2.43B | $2.07B | $1.62B | $1.67B | $1.81B | $1.71B | $1.76B | $4.78B | $1.37B | $1.84B |
| High Forecast | $5.12B | $4.75B | $4.52B | $4.51B | $4.66B | $4.06B | $3.33B | $2.50B | $2.96B | $3.07B | $2.53B | $2.27B | $2.45B | $2.30B | $2.21B | $2.06B | $2.81B | $2.09B | $2.49B | $2.58B | $2.91B | $2.49B | $1.95B | $2.01B | $2.17B | $2.05B | $2.11B | $5.74B | $1.65B | $2.21B |
| Low Forecast | $4.69B | $4.35B | $4.14B | $4.13B | $4.27B | $3.83B | $3.06B | $1.67B | $2.81B | $2.67B | $2.32B | $1.51B | $2.25B | $1.54B | $2.21B | $1.38B | $1.87B | $1.40B | $1.66B | $1.72B | $1.94B | $1.66B | $1.30B | $1.34B | $1.45B | $1.37B | $1.41B | $3.82B | $1.10B | $1.47B |
| Surprise % | - | - | - | - | - | - | - | - | - | -2.10% | -2.49% | 0.90% | 1.01% | 1.25% | - | 1.59% | 1.01% | 0.98% | 0.99% | 0.89% | 1.21% | 0.91% | 1.27% | 1.22% | 1.16% | 1.05% | 1.04% | 1.02% | 0.99% | 1.03% |
6 analysts predict LLY's average Quarter EBITDA for Jun 23 to be $2.44B, with a high of $2.53B and a low of $2.32B. This is 43.41% upper than Eli Lilly and Company's previous annual EBITDA (Mar 23) of $1.70B.
Eli Lilly and Company Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-57.40M | $1.76B | $1.34B | $1.94B | $1.45B | - | $1.90B | $1.73B | $1.11B | $1.39B | $1.36B | $2.12B | $1.21B | $1.41B | $1.46B | $1.50B | $1.25B | $1.33B | $4.24B | $1.13B | $1.15B |
| Avg Forecast | $2.82B | $5.11B | $4.74B | $5.06B | $4.88B | $4.06B | $2.48B | $2.00B | $2.08B | $-161.80M | $1.79B | $1.82B | $1.61B | $1.25B | $1.54B | $1.66B | $1.71B | $1.13B | $1.40B | $1.52B | $1.76B | $1.33B | $1.11B | $1.19B | $1.29B | $1.19B | $1.28B | $4.18B | $1.13B | $1.12B |
| High Forecast | $2.96B | $5.35B | $4.96B | $5.30B | $5.11B | $4.49B | $2.60B | $2.41B | $2.35B | $377.53M | $1.87B | $2.19B | $1.69B | $1.49B | $1.54B | $1.99B | $2.05B | $1.36B | $1.69B | $1.82B | $2.11B | $1.59B | $1.34B | $1.43B | $1.55B | $1.43B | $1.54B | $5.01B | $1.36B | $1.34B |
| Low Forecast | $2.64B | $4.78B | $4.43B | $4.73B | $4.57B | $3.73B | $2.32B | $1.60B | $1.80B | $-970.79M | $1.67B | $1.46B | $1.51B | $996.62M | $1.54B | $1.33B | $1.36B | $906.02M | $1.12B | $1.22B | $1.41B | $1.06B | $890.65M | $952.63M | $1.03B | $953.32M | $1.03B | $3.34B | $906.72M | $892.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.35% | 0.99% | 0.74% | 1.20% | 1.17% | - | 1.15% | 1.01% | 0.98% | 0.99% | 0.89% | 1.21% | 0.91% | 1.27% | 1.22% | 1.16% | 1.05% | 1.04% | 1.02% | 0.99% | 1.03% |
Eli Lilly and Company's average Quarter net income forecast for Sep 23 is $-161.80M, with a range of $-970.79M to $377.53M. LLY's average Quarter net income forecast represents a -109.18% decrease compared to the company's last Quarter net income of $1.76B (Jun 23).
Eli Lilly and Company SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $1.80B | $1.93B | $1.75B | $1.64B | $1.61B | - | $1.56B | $1.59B | $1.58B | $1.69B | $1.58B | $1.55B | $1.57B | $2.90B | $1.55B | $1.70B | $1.41B | $1.59B | $1.52B | $1.86B | $1.62B |
| Avg Forecast | $3.67B | $3.40B | $3.24B | $3.23B | $3.34B | $2.93B | $2.39B | $1.64B | $2.14B | $2.15B | $1.82B | $1.49B | $1.76B | $1.77B | $1.64B | $1.36B | $1.57B | $1.61B | $1.70B | $1.77B | $1.29B | $1.73B | $2.28B | $1.27B | $1.46B | $1.34B | $1.53B | $1.49B | $1.88B | $1.57B |
| High Forecast | $3.80B | $3.53B | $3.36B | $3.35B | $3.46B | $3.02B | $2.48B | $1.97B | $2.20B | $2.28B | $1.88B | $1.79B | $1.82B | $2.12B | $1.64B | $1.63B | $1.89B | $1.93B | $2.04B | $2.12B | $1.55B | $2.07B | $2.74B | $1.52B | $1.76B | $1.61B | $1.84B | $1.79B | $2.25B | $1.88B |
| Low Forecast | $3.49B | $3.23B | $3.08B | $3.07B | $3.17B | $2.84B | $2.27B | $1.31B | $2.09B | $1.99B | $1.73B | $1.19B | $1.67B | $1.42B | $1.64B | $1.09B | $1.26B | $1.29B | $1.36B | $1.41B | $1.03B | $1.38B | $1.83B | $1.01B | $1.17B | $1.07B | $1.23B | $1.20B | $1.50B | $1.25B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.84% | 1.06% | 1.17% | 0.94% | 0.91% | - | 1.15% | 1.01% | 0.98% | 0.99% | 0.89% | 1.21% | 0.91% | 1.27% | 1.22% | 1.16% | 1.05% | 1.04% | 1.02% | 0.99% | 1.03% |
Eli Lilly and Company's average Quarter SG&A projection for Dec 23 is $2.14B, based on 7 Wall Street analysts, with a range of $2.09B to $2.20B. The forecast indicates a 18.78% rise compared to LLY last annual SG&A of $1.80B (Sep 23).
Eli Lilly and Company EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.06 | $1.96 | $1.49 | $2.04 | $1.61 | - | $2.11 | $1.81 | $1.16 | $1.53 | $1.41 | $2.21 | $1.26 | $1.48 | $1.52 | $1.56 | $1.31 | $1.37 | $4.33 | $1.06 | $1.13 |
| Avg Forecast | $3.12 | $5.65 | $5.24 | $5.60 | $5.40 | $4.49 | $2.74 | $2.47 | $2.30 | $-0.18 | $1.98 | $1.73 | $1.78 | $1.91 | $1.70 | $2.29 | $2.45 | $1.96 | $1.89 | $2.12 | $2.37 | $1.71 | $1.56 | $1.48 | $1.52 | $1.40 | $1.45 | $1.31 | $1.35 | $1.31 |
| High Forecast | $3.27 | $5.92 | $5.49 | $5.87 | $5.66 | $4.96 | $2.87 | $2.58 | $2.59 | $0.42 | $2.07 | $1.81 | $1.87 | $2.01 | $1.70 | $2.43 | $2.59 | $2.08 | $2.01 | $2.24 | $2.51 | $1.81 | $1.65 | $1.57 | $1.61 | $1.49 | $1.54 | $1.39 | $1.62 | $1.57 |
| Low Forecast | $2.92 | $5.28 | $4.90 | $5.24 | $5.05 | $4.12 | $2.56 | $2.31 | $1.99 | $-1.07 | $1.85 | $1.61 | $1.67 | $1.79 | $1.70 | $2.20 | $2.34 | $1.88 | $1.81 | $2.03 | $2.27 | $1.64 | $1.50 | $1.42 | $1.46 | $1.34 | $1.39 | $1.25 | $1.08 | $1.05 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.36% | 0.99% | 0.86% | 1.14% | 0.84% | - | 0.92% | 0.74% | 0.59% | 0.81% | 0.67% | 0.93% | 0.74% | 0.95% | 1.03% | 1.03% | 0.93% | 0.95% | 3.31% | 0.79% | 0.86% |
According to 13 Wall Street analysts, Eli Lilly and Company's projected average Quarter EPS for Sep 23 is $-0.18, with a low estimate of $-1.07 and a high estimate of $0.42. This represents a -109.13% decrease compared to LLY previous annual EPS of $1.96 (Jun 23).
Eli Lilly and Company Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $29.27 | $46.29 | 58.15% | Hold |
| BMY | Bristol-Myers Squibb Company | $49.13 | $65.43 | 33.18% | Hold |
| MRK | Merck | $115.86 | $127.74 | 10.25% | Buy |
| JNJ | Johnson & Johnson | $165.52 | $176.29 | 6.51% | Buy |
| GILD | Gilead Sciences | $82.81 | $80.00 | -3.39% | Buy |
| AMGN | Amgen | $332.45 | $286.95 | -13.69% | Buy |
| ABBV | AbbVie | $194.21 | $167.54 | -13.73% | Buy |
| LLY | Eli Lilly and Company | $923.71 | $753.65 | -18.41% | Buy |
LLY Forecast FAQ
Is Eli Lilly and Company a good buy?
Yes, according to 19 Wall Street analysts, Eli Lilly and Company (LLY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 18 'Buy' recommendations, accounting for 94.74% of LLY's total ratings.
What is LLY's price target?
Eli Lilly and Company (LLY) average price target is $753.65 with a range of $300 to $1.15K, implying a -18.41% from its last price of $923.71. The data is based on 19 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Eli Lilly and Company stock go up soon?
According to Wall Street analysts' prediction for LLY stock, the company can go down by -18.41% (from the last price of $923.71 to the average price target of $753.65), up by 24.50% based on the highest stock price target, and down by -67.52% based on the lowest stock price target.
Can Eli Lilly and Company stock reach $1.4K?
LLY's average twelve months analyst stock price target of $753.65 does not support the claim that Eli Lilly and Company can reach $1.4K in the near future.
What is Eli Lilly and Company's current price target trend?
2 Wall Street analysts forecast a $1.08K price target for Eli Lilly and Company (LLY) this month, up 17.24% from its last price of $923.71. Compared to the last 3 and 12 months, the average price target increased by 12.49% and increased by 1.11%, respectively.
What are Eli Lilly and Company's analysts' financial forecasts?
Eli Lilly and Company's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $45.08B (high $46.67B, low $43.09B), average EBITDA is $13.73B (high $14.55B, low $12.82B), average net income is $13.43B (high $14.61B, low $12.22B), average SG&A $10.3B (high $10.93B, low $9.6B), and average EPS is $15.1 (high $16.08, low $14.04). LLY's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $56.57B (high $58.64B, low $53.75B), average EBITDA is $18.23B (high $18.9B, low $17.32B), average net income is $17.73B (high $18.58B, low $16.58B), average SG&A $13.55B (high $14.05B, low $12.87B), and average EPS is $19.61 (high $20.54, low $18.34).
Did the LLY's actual financial results beat the analysts' financial forecasts?
Based on Eli Lilly and Company's last annual report (Dec 2022), the company's revenue was $28.54B, beating the average analysts forecast of $28.36B by 0.65%. Apple's EBITDA was $9.43B, beating the average prediction of $8.21B by 14.89%. The company's net income was $6.24B, beating the average estimation of $6.05B by 3.20%. Apple's SG&A was $6.44B, missing the average forecast of $6.52B by -1.28%. Lastly, the company's EPS was $6.93, missing the average prediction of $7.69 by -9.88%. In terms of the last quarterly report (Mar 2023), Eli Lilly and Company's revenue was $6.96B, beating the average analysts' forecast of $6.86B by 1.41%. The company's EBITDA was $1.7B, missing the average prediction of $1.89B by -9.95%. Eli Lilly and Company's net income was $1.34B, missing the average estimation of $1.82B by -26.21%. The company's SG&A was $1.75B, beating the average forecast of $1.49B by 17.23%. Lastly, the company's EPS was $1.49, missing the average prediction of $1.73 by -13.66%